{"id":"NCT00391092","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.","officialTitle":"A Randomized, Open-label Study to Compare the Effect of First-line Treatment With Avastin in Combination With Herceptin/Docetaxel and Herceptin/Docetaxel Alone on Progression-free Survival in Patients With HER2 Positive Locally Recurrent or Metastatic Breast Cancer.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2014-08","completion":"2014-08","firstPosted":"2006-10-23","resultsPosted":"2015-08-14","lastUpdate":"2015-08-28"},"enrollment":424,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"bevacizumab [Avastin]","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Herceptin","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"This 2 arm study will compare the efficacy and safety of Avastin plus Herceptin/docetaxel, versus Herceptin/docetaxel alone, in patients with HER2 positive locally recurrent or metastatic breast cancer who have not received prior chemotherapy for their metastatic disease. Patients will be randomized 1:1 to receive either Avastin (15mg/kg iv q3weeks) + Herceptin (8mg/kg iv loading dose and 6mg/kg iv q3weeks maintenance) + docetaxel (100mg/m2 iv q3weeks) or Herceptin + docetaxel alone. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"Every 9 weeks up to Week 36, thereafter every 12 weeks until disease progression (up to the clinical cutoff of 30 June 2011, up to 4.75 years)","effectByArm":[{"arm":"Trastuzumab + Docetaxel","deltaMin":13.7,"sd":null},{"arm":"Trastuzumab + Bevacizumab + Docetaxel","deltaMin":16.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0775"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":89,"countries":["Argentina","Australia","Austria","Bosnia and Herzegovina","Brazil","Canada","Czechia","France","Italy","Mexico","Romania","Russia","Spain","Turkey (TÃ¼rkiye)","United Kingdom","Uruguay"]},"refs":{"pmids":["23569311"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":63,"n":206},"commonTop":["Alopecia","Diarrhoea","Nausea","Stomatitis","Asthenia"]}}